Equillium, Inc. (EQ) Stock Score, Valuation & Financial Research

Equillium, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for EQ

Equillium, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.42. These figures are a research snapshot, not a buy or sell recommendation.

What Equillium, Inc. does

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Equillium is a clinical-stage biotechnology company that focuses on developing novel therapeutics for severe autoimmune and inflammatory disorders. The company generates revenue primarily through licensing arrangements, milestone payments, and royalties from collaborative partners, while currently funding its operations through equity financing and capital raises.

Products and services

  • The company's pipeline includes EQ504, a clinical-stage therapeutic, and other assets such as EQ101, EQ102, and EQ302 acquired through mergers and acquisitions.

Customer types

Collaborative partners in the pharmaceutical and biotechnology industry.

Suppliers, materials and equipment

  • Biocon — Exclusive supplier of clinical and commercial drug product for itolizumab (EQ001), manufactured in an FDA-regulated facility in India. Source

Business relationships and partnerships

  • Biocon — A collaboration involving an exclusive supply agreement for clinical and commercial drug product of itolizumab (EQ001) and royalty arrangements for sales outside the Equillium Territory. Source

Business strengths to evaluate

  • Deep understanding of immunobiology to develop novel therapeutics Source

Business risks and research considerations

  • Dependence on third-party collaborators and suppliers for clinical and commercial drug supply Source
  • History of operating losses and reliance on future financing to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

EQ financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.42
Market capitalization:
89.78M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -18.01M
Free cash flow:
USD -22.79M
Cash:
USD 57.16M
Total debt:
USD 584K
EPS:
USD -0.26

What stands out

  • Free cash flow is USD -22.79M, negative for the stored period.
  • The balance sheet shows USD 57.16M of cash versus USD 584K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 56.58M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for EQ

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can EQ fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is EQ likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for EQ to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of EQ's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research EQ

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.